From c98e9ee5f1f1e926a54c63a15aa9eb8ad8faa41e Mon Sep 17 00:00:00 2001
From: Liliana Sanfilippo <lsanfilippo@techfak.uni-bielefeld.de>
Date: Mon, 2 Dec 2024 19:11:40 +0100
Subject: [PATCH] monats formatierung
---
src/data/hptimelinedata.tsx | 102 ++++++++++++++++++------------------
1 file changed, 51 insertions(+), 51 deletions(-)
diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index 3a498bb..65ccc03 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -164,7 +164,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
The multidisciplinary structure of this team evolved naturally as they identified the project’s needs and recruited members who could fill specific roles. Over time, this multidisciplinary structure has continued to develop as the team’s project evolved. Roles became more defined as team members took on specific responsibilities, whether it was refining prime editing systems or crafting
communication strategies for iGEM. The range of experience across the team, from younger students like Malte Lenger in the early stages of their academic careers to more advanced students in later semesters, like Lisa Wiesner, allows for a blend of fresh perspectives and seasoned expertise. This balance helps ensure both the immediate success of the project and the continuity of its progress in the future.
In summary, this interdisciplinary iGEM team demonstrates how a diverse group of individuals with specialized skills can come together to tackle a complex biological project. By combining their expertise the team is able to execute their project holistically, ensuring that each aspect, from experimental design to public outreach, is handled with precision and creativity.</p>],
- months: "February"
+ months: "feb"
},
{
vorname: "Pitching ideas",
@@ -186,7 +186,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>We also considered a project aimed at preventing <b>cyanobacteria blooms</b> using peptides or proteins derived from algae. Cyanobacteria can produce harmful toxins that degrade water quality and threaten ecosystems. The proposed approach focused on utilizing natural algae to develop mechanisms that inhibit the growth of harmful cyanobacteria without disrupting the ecosystem. This project emphasized conservation and biodiversity while addressing a significant environmental issue linked to the climate crisis.</p>,
<p>Throughout our discussions, we recognized that while each project had merit, the <b> Cystic Fibrosis</b> initiative offered the most promise for a targeted approach to a well-defined problem. CF, affecting a substantial number of individuals, provided a clear opportunity for meaningful impact through gene therapy. The insights gained from our examination of other projects informed our approach to CF, allowing us to integrate knowledge from diverse fields and methodologies, ultimately shaping a comprehensive and innovative project direction.</p>
],
- months: "March"
+ months: "mar"
},
{
vorname: "Ideation in Hamburg",
@@ -207,7 +207,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>Throughout our time in Hamburg, we dedicated several hours to reading relevant literature and research papers, both individually and in groups. This collaborative effort allowed us to deepen our understanding of existing projects and innovations in our field. We critically analyzed previous iGEM projects and explored who had worked on similar ideas, which helped us identify gaps in the research and potential avenues for our own project.
Our discussions naturally flowed into brainstorming sessions where we reflected on the impacts we wanted to achieve. We explored essential questions: What effects do we aim to have on society? What activities can we plan to gather evidence about how our work will resonate with the community? How can we effectively engage with stakeholders and share our findings?
In addition to structured brainstorming, we exchanged ideas informally during breaks and meals, fostering a creative atmosphere. By the end of the weekend, we had not only strengthened our team bonds but also clarified our vision for the project ahead. The insights gained from our discussions and readings laid a solid foundation for our future work, allowing us to approach our project with renewed focus and purpose.</p>],
- months: "March"
+ months: "mar"
},
{
vorname: "Max",
@@ -292,7 +292,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Are most of the other patients you know in good health like you?" a="No. Another boy my age got a fungal infection and does not have long time left to live. " />
</>,
summary: "We reached out to Max, a friend of a teammate, to gain insights into the needs and experiences of CF patients. Our discussions revealed the challenges faced by CF patients, even those in relatively good health, and emphasized the ongoing need for new treatment options. Max's candid sharing of his experiences highlighted the limitations of current modulators, the importance of lung function, and the impact of treatments on quality of life. This meeting transformed our project perspective, urging us to prioritize safety and real-world benefits in our design. Ultimately, Max's influence led us to focus on lung-targeted gene therapy instead of a diagnostic approach, reinforcing our commitment to Integrated Human Practices.",
- months: "April",
+ months: "apr",
/*interview:<iframe title="Bielefeld-CeBiTec: Interview with Max Beckmann (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/16501867-a687-4205-949a-51ead876e109" frameborder="0" allowfullscreen="" sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>,*/
},
{
@@ -309,7 +309,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteNachname: "Sanfilipo, Teammember",
quoteVorname: "Liliana",
summary: "Our team members had a productive visit to the Hannover Messe, focusing on synthetic biology and research advancements. They explored innovative technologies and networked with potential sponsors, gaining valuable insights to help enhance our project and drive future developments. The event was a great opportunity to connect with industry leaders and learn about cutting-edge solutions in the field.",
- months: "April",
+ months: "apr",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/hp/hannover-1.webp",
},
{
@@ -333,7 +333,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
On the other hand, LNPs offer a scalable and re-dosable alternative. LNPs have the advantage of a larger packaging capacity, allowing them to carry more complex genetic instructions or larger gene-editing tools, such as prime editors. They are also easier and cheaper to produce on a large scale, making them an attractive option for widespread clinical applications. A significant benefit of LNPs is their lower immunogenicity, which reduces the risk of adverse immune reactions upon repeated dosing. However, LNPs currently face challenges in specific targeting compared to AAVs. AAVs have a higher precision in targeting specific tissues, while LNPs still need optimization for targeted delivery to areas like the lungs.</p>],
implementation: [<p>Prof. Müller’s insights directly inform the implementation of our iGEM project, where we aim to design novel prime editors that are small enough to be delivered efficiently, while also exploring LNPs <OurLink path='engineering'tabId='delivery' scrollToId='del1head' text="exploring LNPs"/> as a scalable and re-dosable alternative to AAVs. By tailoring our approach to address the specific challenges of CF, such as mucus penetration and lung cell targeting, we can enhance the precision and efficacy of gene therapy. These innovations have the potential to set new standards in the field and contribute to broader research on genetic disease treatment.</p>],
summary: [<p>In our interview with Prof. Dr. Kristian Müller, we explored the revolutionary potential of prime editing as a next-generation gene editing technology. Prof. Müller highlighted the advantages of prime editing over traditional CRISPR-Cas systems, particularly its ability to make precise genetic modifications without double-strand breaks, thus reducing off-target effects. He emphasized the importance of optimizing delivery systems, such as <OurLink path='engineering'tabId='delivery' scrollToId='del1head' text="AAV and LNPs"/>, and discussed the ethical considerations and biosafety measures crucial for advancing gene therapy. The interview underscored the significance of Cystic Fibrosis as a model disease, given its prevalence and the potential for impactful treatments through targeted genetic corrections.</p>],
- months: "April",
+ months: "apr",
interview:<><iframe title="Bielefeld-CeBiTec: Interview Müller AAV vs LNP (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/0613b6b8-7755-4373-9d86-9910fe30781f" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe><p>This interview was recorded on video at a later date.</p></>,
},
{
@@ -373,7 +373,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
- months: "April"
+ months: "apr"
},
{
vorname: "Visiting ",
@@ -731,7 +731,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</>,
references: <MattijsInterviewSources />,
summary: "Our discussion with Mattijs Bulcaen from KU Leuven provided critical insights into the complexities of using prime editing for CF therapy. As we began designing our prime editor, Mattijs highlighted challenges specific to targeting the CFTR F508del deletion, including the influence of mismatch repair systems and chromatin organization on editing efficiency. He introduced us to advanced techniques, such as PE3b systems and dsgRNAs, and recommended using the 3’ stem loop motif from his research to enhance our pegRNA design. Additionally, he advised utilizing HEK cell lines for screening due to their ease of handling and reduced mismatch repair activity. These insights directly influenced our design choices and helped refine our approach to developing an effective prime editing strategy.",
- months: "june"
+ months: "jun"
},
{
vorname: "Integrate Insights",
@@ -762,7 +762,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<b>Scientific Advancements:</b> Improved the efficiency of Prime Editing by incorporating a novel RNA structural element, with further efforts to optimize the Prime Editing protein complex for broader applicability beyond Cystic Fibrosis.
</li>
</ul>],
- months: "june"
+ months: "jun"
},
{
vorname: "'Der Teuto ruft'",
@@ -779,7 +779,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Asal",
quote: "I had a great time educating the kids about gene therapy and CF in a playful way, and there were some very interesting conversations with the parents.",
summary: [<p> <OurLink tabId='teutoruft' scrollToId="teuroruft-heading" path='human-practices' text="Der Teuto ruft!"/> is a community event in Bielefeld where iGEM Bielefeld participated to raise awareness about Cystic Fibrosis (CF) and gene therapy. They engaged children through interactive experiments, such as creating lung models and simulating mucus to help them understand the challenges faced by CF patients. Adults were informed about their gene therapy project and had meaningful discussions about the implications of CF treatment. Collaborating with other institutions like the life science student initiative btS, the team expanded their outreach. Despite changeable weather, the event was a success in educating the public and improving science communication.</p>],
- months: "June"
+ months: "jun"
},
{
vorname: "Julia",
@@ -826,7 +826,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="How do you handle communicating about her illness?" a="We try not to make a big deal of it. When I looked for information, I found what we needed. There’s nothing we’ve really felt was missing." />
</>,
summary: "Julia's insights shifted our focus to the support systems surrounding CF patients. She highlighted the societal implications of CF, including rising healthcare costs due to the long-term nature of treatment and the financial burdens faced by families. Additionally, Julia emphasized the emotional strain that accompanies the illness, alongside the complexities of parenting a child with CF. Importantly, she affirmed that most children adapt well to inhalative therapies, reinforcing our planned delivery method for gene therapy. This interview enriched our understanding of the challenges faced by families and enabled us to better compare the experiences of CF patients in Germany to those in other countries.",
- months: "june"
+ months: "jun"
},
{
title: "Prof. Dr.",
@@ -856,7 +856,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
implementation: "x",
summary: " David Liu, the principal investigator behind prime editing systems, has significantly contributed to the development of advanced gene editing techniques, including applications for the CFTR mutation F508del. His research provided valuable insights for our project, leading us to adopt a system based on the PE6c and PE4 prime editors. Although we couldn't directly engage with Liu or his team, the impact of his work is evident in our gene editing approach for PreCyse. Notably, Liu's recent talk at the 'State of CRISPR and Gene Editing 2024' conference highlighted advancements such as improved reverse transcriptases and their applications in prime editing. The publication of his findings on CFTR F508del correction in July 2024 further validated our design choices for pegRNA and offered new strategies for optimizing our approach.",
- months: "June",
+ months: "jun",
references: <LiuInterviewSources/>,
},
{
@@ -917,7 +917,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
a="It’s mainly interdisciplinary. A lot of funding comes from industry, like BioNTech, or foundations like Mukoviszidose e.V., which funds research on Cystic Fibrosis. But in terms of practical research, it’s usually biologists or biotechnologists. Without industry support, research can struggle due to a lack of funding, so having backing is essential." />
</>,
summary: "Our discussion addressed the complexities of Cystic Fibrosis (CF) treatments, focusing on gene therapy and health insurance processes. We learned about the regulatory challenges gene therapies face, particularly regarding the European Medicines Agency (EMA) and the AMNOG process for reimbursement assessments. Public insurers impose stricter guidelines than private insurers, emphasizing the importance of early intervention in CF and the need for adaptable policies for atypical cases. We recognized the high costs associated with gene therapies and incorporated cost-benefit analysis into our project planning. Following the interview, we refined our approach to include straightforward delivery methods and attended a GxP course for regulatory compliance. Engaging with start-ups further informed our practical implementation strategies, ensuring our project aligns with both scientific and regulatory needs.",
- months: "june",
+ months: "jun",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/zoom-nicole.webp",
},
{
@@ -939,7 +939,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>Understanding rigorous quality control processes was another key takeaway, enabling us to implement checks that will boost the reliability and safety of our therapeutics. These comprehensive insights have not only supported our current goals but also prepared us for future challenges, equipping us with the tools to navigate the complexities of research and therapeutic development.</p>],
implementation: [<p>Discussions with industry experts have provided invaluable insights into the production of LNPs{/* [LINK LNPcycle] */}, a crucial aspect of our project. We have identified innovative manufacturing techniques and quality control procedures that we can integrate into our processes. This knowledge not only supports our immediate objectives but also positions us to overcome future challenges in developing effective therapies.</p>],
summary: [<p>During discussions with industry experts at Achema 2024, we gained valuable insights that will have a significant impact on our project and provide us with innovative manufacturing techniques and quality control procedures that we are now integrating into our workflows. These insights will help us to optimise our production processes to achieve more efficient and reliable results in therapeutic development. The new knowledge supports our current goals and prepares us for future challenges in the development of effective therapies</p>],
- months: "june",
+ months: "jun",
pictureurl_aim:"https://static.igem.wiki/teams/5247/photos/hp/achema1.webp",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/hp/achema2.webp",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/achema3.webp",
@@ -980,7 +980,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</ol>,],
summary: "In the visit with Katrin Westhoff, we participated in physiotherapy sessions for children, including those with Cystic Fibrosis (CF). We observed that breathing therapy is beneficial for various illnesses and learned techniques that can be practiced at home. Sessions last 30 to 60 minutes, combining manual therapy with playful elements. While older children engaged well, infants often found the exercises uncomfortable. Importantly, both Katrin and parents noted that children could inhale without issues from an early age, reinforcing our focus on inhalation delivery methods for therapies.",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/hp/besuch-westhoff/untitled-design.png",
- months: "june"
+ months: "jun"
},
{
title: "Dr.",
@@ -1006,7 +1006,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Storage conditions were strictly managed at 4 °C, and pipetting/mixing techniques were refined to ensure quality consistency. Quality control was expanded to include fluorescence testing, zeta potential measurements, and light scattering, alongside cytotoxicity tests.
These improvements not only address transfection challenges but also strengthen our foundation for future LNP applications. </p>],
summary: "The aim of the contact was to address challenges in LNP transfection and improve formulation protocols for enhanced gene delivery. Dr. Radukic highlighted the importance of lipid-to-nucleic acid ratios, recommending adjustments like 10:1 for better transfection efficiency. He also emphasized optimizing pH and buffer composition, as well as strict storage and mixing practices. Additionally, quality control measures such as fluorescence testing and zeta potential analysis were suggested to ensure LNP stability. These insights were implemented into the project, improving transfection efficiency and paving the way for future LNP applications.",
- months: "June"
+ months: "jun"
},
{
title: "Prof. Dr.",
@@ -1068,7 +1068,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</>,
summary: "In summary, through the interview with Prof. Dr. Wischmeyer and the collaboration with his employee Dr. Oliver Dräger, we gained valuable insights and optimized our approach to effectively investigate and measure the functionality of the CFTR ion channel, thereby determining the efficiency of our prime editing strategy.",
- months: "june"
+ months: "jun"
},
{
vorname: "Joshua",
@@ -1114,7 +1114,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/joshua-zoom.webp",
references: <JoshuaInterviewSources />,
summary: "Joshua, a CF parent living in Thailand, shared his experiences about the severe challenges of accessing CF care in regions like Southeast Asia. His story highlighted the racial bias and lack of medical knowledge about CF in these areas. This interview prompted the team to reflect on their focus on the F508del mutation, questioning if their research was biased towards more commonly studied mutations. After revisiting their research process, they found that the F508del mutation remains globally relevant, yet the experience reinforced the importance of addressing gaps in healthcare and research for underrepresented regions.",
- months: "July"
+ months: "jul"
},
{
vorname: "Close the Loop",
@@ -1154,7 +1154,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
- months: "july"
+ months: "jul"
},
{
title: "Prof. Dr.",
@@ -1192,7 +1192,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>We developed our mutation candidates on this basis. {/*[link zum Cycle oder New Part ?]*/}</p>
],
summary: "In our discussion with Prof. Dr. Hammer, we explored several theoretical approaches in enzyme engineering, including PAM engineering, chimeric proteins, Phage-Assisted Continuous Evolution (PACE), and rational design involving zinc-finger mutations. We evaluated the potential of using structural simulations with AlphaFold 3 and the construction of chimeric proteins. The conversation highlighted the importance of analyzing homologous mechanisms through sequence alignments to identify structural similarities in catalytic centers. We also discussed targeted mutations, such as substitutions to alanine, and the development of a nickase assay. Overall, we concluded that transferring mutations to homologous proteins is a promising rational approach for optimizing enzyme function.",
- months: "July"
+ months: "jul"
},
{
vorname: "Steffen Bira and",
@@ -1232,7 +1232,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What is Corden Pharma's position on projects involving gene therapy?" a="Corden Pharma operates as a service provider, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and excipients rather than developing therapeutic products. Consideration should be given to the intellectual property status of the lipids used in LNP formulations, particularly for commercial applications."/>
</>,
summary: "The primary goal of the communication with Steffen Bira and Serra Gürcan from Corden Pharma was to explore the use of Lipid Nanoparticles (LNPs) in gene therapy and inhalation treatments. Corden Pharma recommended consulting specialists for assessing spray drying feasibility, while highlighting the importance of testing LNP stability under various conditions. Their LNP starter kits are optimized for stability and encapsulation efficiency, with potential for lipid modifications to enhance cellular uptake. They also confirmed that antibodies can be incorporated into LNPs and emphasized considering intellectual property when selecting lipids. Based on Corden Pharma’s insights, we switched to their kit #2 for our project, hoping to improve the stability and efficiency of our LNP formulations. Their guidance also opened opportunities for targeted therapies and collaborations. This feedback will continue to enhance our testing and therapeutic approaches.",
- months: "july",
+ months: "jul",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/hp/hp-corden-zoom.png"
},
{
@@ -1248,7 +1248,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Kaya",
quote: "It was amazing to see how exciting the conversations were with future STEM scientists and to hear the fresh perspectives from young minds. The entire experience was both inspiring and energizing.",
summary: [<p>MINT Sommer 2024 is a program for high school graduates interested in STEM fields, and iGEM Bielefeld participated to raise awareness about CF and promote their gene therapy research. The team engaged future scientists, explaining the iGEM competition and their synthetic biology approach to address CF. Using insights from previous workshops, they designed interactive activities to make the complexities of CF accessible to attendees. Over two weeks, they formed meaningful connections with professors, students, and STEM professionals, enriching their research discussions. Overall, the event helped improve their science communication skills and fostered valuable professional growth.</p>],
- months: "July"
+ months: "jul"
},
{
title: "Dr.",
@@ -1277,7 +1277,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
],
implementation: [<p>On the basis of Svenja’s and other opinions on the topic, we decided not to try implementing a PACE system. </p>],
summary: "We reached out to Svenja Vinke, a former iGEMer and Postdoc, to gain insights on using phage-assisted continuous evolution (PACE) for optimizing our prime editing. Svenja explained that a PACE approach is not feasible for our nickase candidates due to several reasons: it requires too much time, endonucleases are likely too large for optimization, unspecific cutting can kill bacterial cells, and prime editing is less effective in E. coli than in human cells. Based on Svenja's feedback and other expert opinions, we decided against implementing a PACE system for our project.",
- months: "July"
+ months: "jul"
},
{
title: "Dr.",
@@ -1296,7 +1296,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "The discussion was very informative in terms of how we should approach this topic and focused primarily on the important factors that need to be considered when planning the handling of patient cells. These include which legal principles need to be observed, data protection, ethical considerations and, above all, detailed and specific information for the donor. It also made us look at the situation from many different angles and consider the risks of worst-case scenarios. Overall, this interview was very useful to us, and we were able to use the information we gained to develop a kind of guideline that allowed us to approach this sensitive topic, which was new to us, with a certain degree of confidence. ",
implementation: "Based on the knowledge we have gained, we have drawn up guidelines for our handling of the cells. We used this guide when handling the patient cells, to ensure they were handled in an ethically correct manner.",
summary: "This interview focused on the ethical and legal considerations of handling patient cells, we sought to determine whether our project required an ethics vote and to gather guidelines on data protection and patient consent. The expert emphasized the importance of providing patients with a detailed consent letter and privacy policy, clearly explaining how their cells and data will be used, who will have access, and the time span involved. This conversation helped us understand key legal and ethical principles, especially regarding transparency with donors. We used these insights to develop guidelines for handling patient cells, ensuring we approached this sensitive process with confidence and ethical care.",
- months: "July",
+ months: "jul",
pictureurl_interview:"https://static.igem.wiki/teams/5247/integrated-human-practices/interview-berens.webp",
},
{
@@ -1319,7 +1319,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Lastly Mattijs explained how he plans to deliver the prime editing complex to the patient, and we evaluated the advantages and disadvantages of delivery strategies, including our very own LNP approach.</p>],
implementation: [<p>When planning how to test and confirm editing by our own constructs, we were largely inspired by the information given to us by Mattijs. For example, we tested prime editing in the HEK293 cell lines we spoke about with Mattijs and used halide sensitive eYFP to check for CFTR function. Also, we tried differentiating wild-type and F508del cells using patch clamp. Unfortunately, a lot of the methods mentioned were not usable for us because of time constraints, but are still valuable for future projects and research built upon PreCyse. </p>],
summary: "We visited Mattijs Bulcaen in Leuven to enhance our understanding of CFTR F508del models and editing confirmation. During the visit, we examined HEK293T cell lines that stably overexpress wild-type CFTR and the F508del variant. Mattijs demonstrated how to use a 3HA tag for visualizing protein processing and discussed methods for assessing CFTR functional recovery. We also compared Sanger and Nanopore sequencing techniques and evaluated delivery strategies for our prime editing complex. The insights from this visit guided our project, leading us to test prime editing in HEK293T cells using halide-sensitive eYFP. While some methods were not feasible due to time constraints, they laid the groundwork for future research in the PreCyse project.",
- months: "july"
+ months: "jul"
},
{
vorname: "Collaborations",
@@ -1371,7 +1371,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>In the process of our interaction with Kai, we learned about the various methods employed in enzyme engineering. He demonstrated the complexity of this field of research and emphasized the importance of choosing the right approach. As a former iGEMer, Kai, inspired by his past experiences, is highly motivated and determined to develop an outstanding project. He pointed out that we cannot rely on classical methods such as directed evolution, but instead should use a rational approach to select mutation candidates. His insights and enthusiasm have encouraged us to think critically and pursue innovative solutions in our work. </p>],
implementation: [<p>We incorporated Kai's insights into our project by shifting our approach to enzyme engineering. By focusing on a more targeted approach, we were able to refine our enzyme optimization process, ensuring that the modifications we made were based on informed, calculated decisions. This not only streamlined our research but also improved the chances of success by reducing the trial-and-error inherent in traditional methods. </p>],
summary: "The team reached out to Kai Schülke, a former iGEM participant and enzyme engineering expert, for guidance on developing a nickase from the endonucleases in use. Kai emphasized the need for a rational, targeted approach rather than traditional methods like directed evolution. His insights helped the team refine their enzyme optimization process, making it more strategic and efficient. This shift reduced trial-and-error efforts and improved the chances of success, driving innovation in their project.",
- months: "July"
+ months: "jul"
},
{
title: "M.Sc.",
@@ -1392,7 +1392,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Pichia pastoris (SMD1163) is a promising option for expressing SpuFz1 nickase variants. Refining expression strategies based on expert insights is crucil for success. Nils provided practical tips on yeast expression, including optimizing growth conditions and fine-tuning induction protocols.</p>],
implementation: [<p>We adapted our expression strategy for Fanzor nickases in yeast by incorporating the Pichia pastoris strain (SMD1163) and the provided expression vector into our experiments. Following Nils' detailed protocols and plasmid map, we optimized key steps, enhancing expression efficiency and protein yield.</p>],
summary: "The team sought expert advice from Nils to optimize yeast expression for Fanzor nickases. Nils provided invaluable guidance on addressing potential challenges and troubleshooting the process. He supplied the Pichia pastoris (SMD1163) strain along with a suitable expression vector, crucial for expressing SpuFz1 nickase variants. Additionally, he shared detailed protocols for yeast transformation and growth optimization, enabling the team to replicate his methods effectively for their experiments.",
- months: "July",
+ months: "jul",
},
{
title: "Dr.",
@@ -1442,7 +1442,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What rights do patients have in relation to their samples, and how are these rights safeguarded in your biobank?"
a="Patients have the right to revoke their consent at any time, which can be done at the clinic or biobank. The trustee, acting as an intermediary, will notify BOWL and DIZ to destroy the corresponding samples or data." />
</>,
- months: "august"
+ months: "aug"
},
{
vorname: "'Schüler*innen Akademie'",
@@ -1457,7 +1457,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteNachname: "Lange, Teamm",
quote: "It was wonderful to be part of the Student Academy and to experience how much we learned while teaching. Sharing our knowledge and seeing the students' enthusiasm was incredibly rewarding, even though we couldn't convey everything in just one session.",
summary: [<p>The CeBiTec Student Academy at Bielefeld University provides high school students with hands-on experience in biotechnology and molecular biology, supported by the Osthushenrich Foundation and Detmold district government. iGEM Bielefeld participated by guiding students through a nanopore sequencing experiment, teaching them about lab work, experiment preparation, and safety protocols. The team also presented their iGEM project, PreCyse, giving students insight into real-world research projects and synthetic biology. Many students were excited by the iGEM concept and expressed interest in joining during their future studies. Overall, the academy helped inspire students to explore STEM fields and gain practical scientific skills.</p>],
- months: "August"
+ months: "aug"
},
{
vorname: "Present evidence",
@@ -1497,7 +1497,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</li>
</ul>
],
- months: "august"
+ months: "aug"
},
{
vorname: "Benjamin",
@@ -1555,7 +1555,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Would you be willing to support us in our project? Would you dry our LNPs?" a="The spray dryer requires 5 mL of a solution with 5% solid content. Among these solids, the lipid content can be adjusted between approximately 0.2% and 15%, while the RNA content can range from 0.02% to 1.5%. The remaining percentage is composed of excipients. We’ve published recovery rates of >70%. You can send us the mRNA and LNP components to encapsulate and dry."/>
</>, */
summary: "The conversation focused on spray-drying LNPs, emphasizing the shelf life of RNA-based formulations, optimal storage conditions, and technical requirements for the drying process. Corden Pharma shared insights on the protocol, highlighting the need for testing each LNP formulation individually for stability. AI technology is used to optimize LNP formulations, and potential collaborations were discussed, including support for drying LNPs.",
- months: "august"
+ months: "aug"
},
{
vorname: "Max",
@@ -1576,7 +1576,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
With regard to points five and six, he clarifies that no special hygiene items are required for the stay as long as the toilets are cleaned regularly and there is an additional service for the washbasins. He explains that the sources of danger can be significantly reduced by regular cleaning and the presence of toilet lids, which eliminates the need for special hygiene measures.
He also argues that contactless facilities are not necessary as people wash or sanitise their hands after using the toilet anyway. Finally, he asks whether sources are needed for the hygiene concept and offers his help to create a revised version, which he would then like to review again before it is forwarded to Mr Johannfunke.</p>],
- months: "August"
+ months: "aug"
},
{
title: "Dr.",
@@ -1624,7 +1624,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Thank you so much for your time and insights!" a="You’re welcome! I’m glad I could help." />
</>,
summary: "We identified several crucial insights to guide our project development. Nano-capsules were found to be more stable than nano-complexes, making them our preferred formulation choice. We will utilize chitosan to enhance mRNA stability due to its positive charge, while capsaicin was deemed irrelevant for our purposes. For transfection, we will use OptiMEM as the medium, removing antibiotics 24 hours prior to the procedure. We will assess stability with a Zetasizer and evaluate cytotoxicity using the MTT test. Additionally, we are exploring nasal spray and dry powder formulations to improve nanoparticle delivery. These insights will significantly shape our approach to optimizing mRNA delivery systems.",
- months: "August"
+ months: "aug"
},
{
title: "Dr.",
@@ -1643,7 +1643,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p></p>],
implementation: [<p></p>],
summary: "",
- months: "August",
+ months: "aug",
},
{
vorname: "GxP course",
@@ -1673,7 +1673,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
One of the key speakers during the GXP course was <HPLinktoOtherHPTab tab="gxpexpert" text="Dr. Marcus Berger" />, whose expertise was invaluable to me and the entire team. After the course, I had the opportunity to ask Dr. Berger some questions, further deepening my understanding of the practical applications of GXP in research. The connection with Dr. Berger has been highly beneficial, as his insights helped shape key aspects of our project’s development and compliance with industry standards. His guidance will continue to be a valuable resource for our team moving forward.
Through this training, I feel better positioned to contribute to the team’s efforts, ensuring our project adheres to global safety and ethical guidelines. This experience has strengthened our approach and set a solid foundation for future progress, ensuring that our research, public engagement, and potential clinical applications continue to meet the highest regulatory standards. </p>],
summary: "Kaya, a member of the iGEM Bielefeld 2024 team, completed an intensive one-week GXP (Good Practice) training, which covered Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP). The training provided valuable insights into maintaining high standards of quality, safety, and ethics throughout the research process. Kaya learned crucial skills, such as documenting research processes for reproducibility, creating standard operating procedures (SOPs), and conducting risk assessments using techniques like Failure Mode and Effects Analysis (FMEA). This knowledge is essential for advancing their Cystic Fibrosis gene therapy project toward clinical trials and ensuring compliance with regulatory standards. Dr. Marcus Berger, a key speaker in the course, provided additional guidance, offering valuable insights that will continue to benefit the team.",
- months: "august",
+ months: "aug",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/gxp/gxp-course-kaya.webp",
pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/for-wiki-texts/gxp/gxp-course-group.webp",
},
@@ -1710,7 +1710,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<b>Broader Perspectives:</b> Leveraged diverse interactions to gain new perspectives that enhanced the project's impact and direction.
</li>
</ul>],
- months: "September"
+ months: "sep"
},
{
title: "",
@@ -1737,7 +1737,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What are the next steps in implementing the hygiene concept?" a="It is essential that the concept be implemented in small, strategic steps. At the same time, it is vital that the rectorate and other decision-makers be consulted on a regular basis to ensure that this matter remains at the forefront of discussions. Furthermore, it is of great importance to engage in political lobbying to secure additional support for this issue." />
</>,
summary: "We got in touch because there was an acute hygiene problem for particularly vulnerable groups like immunocomprised persons at the university. We learnt from the exchange that despite a well-developed hygiene policy, strategic steps are still needed, especially to overcome bureaucratic hurdles. We have integrated these lessons into our project by focusing on continuous collaboration with the Central contact point Barrier-free and other decision-makers.",
- months: "September"
+ months: "sep"
},
{
title: "Dr.",
@@ -1760,7 +1760,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
implementation: [<p>The data were incorporated by confirming that the F508del mutation is not only the most common in Europe but also globally, including in Asia, highlighting a broader perspective and contributing to a significant horizon expansion in understanding the mutation's worldwide prevalence. This finding lends support to the idea that existing therapies targeting the F508del mutation will be effective for many patients worldwide, thereby providing a solid foundation for treatment. As a starting point, this is promising, but future efforts will focus on adapting therapies to address other, rarer mutations found in specific populations.
</p>],
summary: "The contact provided valuable insights into Cystic Fibrosis (CF) in Asia and confirmed that the F508del mutation is the most common, as it is globally. However, the genetic diversity observed in Asia, together with the exacerbation of symptoms by environmental factors such as air pollution, highlights the need for more region-specific research. Future efforts will focus on refining treatments for rarer mutations and improving diagnostic accuracy in Asian populations.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="Should we explain our project a little bit in the beginning?" a="That would be great."/>
<QaBox q="Okay. As I wrote to you in the email, we are part of the Bielefeld-CeBiTec item team in Germany this year, and we have a project called Precyse, where we want to develop a platform for next-generation prime editing. With that, we aim to tackle CF mutations, starting with the F508del mutation. The complex should be adaptable for different mutations with minor changes. Essentially, we want to operate like Cas-based projects using prime editing tools but may transition to using a fanzor nickase in the future. Currently, we are working on a delivery system utilizing lipid nanoparticles to transport our complex into the lungs. These nanoparticles will be loaded with mRNA and designed for inhalation, similar to how asthma medications are delivered. Our goal is to advance personalized medicine and improve the standard of living for those affected by the disease, especially since a friend of one of our team members has Cystic Fibrosis and shares insights on the challenges faced by those with the condition." a="That's a very nice summary. I have a couple of clarifying questions. Are you undergraduates?" />
@@ -1837,7 +1837,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What are your thoughts on using lipid nanoparticles (LNPs) versus other delivery systems, like AAV vectors?" a="Lipid nanoparticles (LNPs) are a promising delivery system for many genetic therapies, but they have limitations. While LNPs can effectively target certain organs, such as the lungs and liver, they cannot cross the blood-brain barrier and thus unsuitable (for now) to target neuronal pathologies. For these conditions, adeno-associated viral (AAV) vectors may be more effective, as they exhibit an inherent ability to cross the blood-brain barrier. For CF specifically, we have used LNPs to deliver sup-tRNAs directly to the lungs. We teamed up with an US company that develops safe LNPs used also for vaccines. Delivery methods like intratracheal instillation—where the LNPs are introduced into the trachea—allow for targeting the lung tissue more directly, which is critical for treating CF." />
<QaBox q="How do you view prime editing compared to other gene editing technologies?" a="Prime editing is an exciting development in the field of gene editing, but it is important to recognize that no single approach is universally superior. Technologies like prime editing, CRISPR-Cas, and our own tRNA-based therapies each have their strengths and limitations. For instance, prime editing offers a highly precise method for correcting mutations directly at the DNA level, potentially providing a one-time, lifelong cure. However, our approach, which focuses on restoring mRNA translation, does not introduce permanent changes to the genome and unforeseen, also individuum-specific side effects, can be counteracted by immediate termination of the therapy. In turn, it requires continuous re-administration over time. Ultimately, the safety and efficacy of any approach must be carefully weighed. We are not yet at a point where we can definitively rank these technologies because the field is still evolving. Each approach has potential, and the choice of which to use will likely depend on the specific disease and mutation being targeted." />
</>,
- months: "September",
+ months: "sep",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/interview-ignatova/interview-ingatova.webp ",
},
{
@@ -1867,7 +1867,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Additionally, the emphasis on the need for continued advancements in enzyme development and gene therapy has guided us to balance immediate therapeutic benefits with long-term research goals. This ensures that our project addresses both current needs and future possibilities in CF treatment.
By integrating these insights, we aim to ensure our project not only advances scientific understanding but also meets the practical needs of CF patients, ultimately leading to more effective and accessible treatments. </p>],
summary: "The aim of our outreach to Cystic Fibrosis (CF) patients was to gain insights into their daily experiences and how recent treatment advancements have affected their lives. Partnering with MukoDino allowed us to distribute a survey widely, as interviews were limited. Through discussions with patients, we learned about the challenges posed by current treatments, emphasizing the need for therapies that simplify management and reduce physical strain. This feedback has driven our focus on developing more efficient inhalation therapies using spray-dried lipid nanoparticles (LNPs) to deliver gene-editing tools directly to the lungs. We also recognized the global disparities in CF care, motivating us to consider scalability and accessibility for those in resource-limited regions. Patient insights underscored the importance of personalized treatments tailored to individual genetic mutations, prompting us to prioritize enzyme development and gene therapy in our research. Overall, these insights have shaped our project to align closely with the real-world needs of CF patients, aiming for impactful and accessible solutions.",
- months: "September",
+ months: "sep",
interview: <>
<QaBox q="How did you come up with the name ‘Muko-Dino’?" a="The name ‘Muko-Dino’ has a personal history. At a Cystic Fibrosis meeting, another patient joked that I, as a 58-year-old Cystic Fibrosis patient, was a ‘Muko-Dino’. The name alludes to my age, because in the past, Cystic Fibrosis patients had a much shorter life expectancy. So it was unusual for someone with the disease to still be so active at my age. The name stuck - initially as a joke, but I have since adopted it as a kind of nickname." />
<QaBox q="When were you diagnosed with Cystic Fibrosis?" a="I was diagnosed at the age of six after a sweat test. I had lost a lot of weight in the first year of my life and Cystic Fibrosis was already suspected, but it took a while before the diagnosis was actually confirmed." />
@@ -1918,7 +1918,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
implementation: [<p>These findings directly influenced several key areas of the project. We adapted the project to emphasise ease of use and minimal disruption to patients' daily lives. For example, we focused on developing a therapy delivery system that was as non-invasive as possible. Recognising the mental health challenges, we integrated our project with a simple therapeutic method to reduce the mental burden on patients. We have emphasised transparency in communicating the benefits, risks and expectations of gene therapy to ensure that patients have a realistic understanding of the potential outcomes. This includes working closely with patient organisations to disseminate clear and accurate information. We are actively engaging with CF patient communities and healthcare professionals to gather ongoing feedback and ensure that the project evolves based on real patient experiences and challenges. Therefore we used our survey to gather feedback from patients and their families.
By integrating these insights, we aim to create a gene therapy project that addresses not only the medical needs, but also the emotional and practical concerns of CF patients and their families. </p>],
summary: "Our project aims to address the psychological and medical challenges faced by Cystic Fibrosis (CF) patients and their families, particularly regarding gene therapies. We engaged with psychologists and gathered insights from patients and caregivers, revealing significant emotional strain and a mix of optimism and concern about new treatments. Key findings highlighted the importance of psychological support and the practicality of therapies in ensuring patient engagement. In response, we are developing a user-friendly therapy delivery system that minimizes disruption to daily life while emphasizing transparent communication about treatment risks and benefits. Our goal is to create a comprehensive gene therapy solution that meets the medical and emotional needs of CF patients.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="Which psychological challenges are particularly relevant for Cystic Fibrosis patients?" a="Psychological problems are often a major issue for Cystic Fibrosis patients. Many patients experience anxiety and depression, and their parents are also often affected. This is exacerbated by the constant strain and stress associated with the disease. Special attention is therefore paid to psychological support during diagnosis and ongoing treatment. Regular screenings for anxiety and depression as well as the early involvement of parents in the treatment process are central components of care."/>
<QaBox q="What significance do the new therapies have for Cystic Fibrosis patients?" a="New therapies are ‘game changers’ for Cystic Fibrosis patients, as they significantly improve life expectancy and quality of life. In the past, Cystic Fibrosis was mainly a paediatric disease with a short life expectancy. Today, new therapies make it possible to significantly extend life expectancy and improve quality of life. Nevertheless, the disease persists, and patients still require comprehensive treatment. Improving quality of life through early and continuous therapy therefore remains of great importance."/>
@@ -1964,7 +1964,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "The interview provided the iGEM team with valuable advice regarding their Prime Editing project and especially on their planned nickase assay. Dr Saito gave detailed feedback on technical challenges, especially with protein expression in E. coli, and suggested switching to yeast for better results. He also encouraged the team to plan carefully, given the project's complexity, and offered guidance on future experiments.  ",
implementation: "We have adapted our planned nickase assay according to Dr Saito's advice and changed it accordingly to expression of the RNP complex using yeast.",
summary: "The interview aimed to gain insights into protein engineering, particularly regarding Fanzor (SpuFz), and to get feedback on potential nickases and a planned nickase assay. Dr. Saito provided valuable advice, suggesting the use of yeast for protein expression over E. coli due to technical challenges and encouraged careful planning. Based on his feedback, the iGEM team has adapted their nickase assay to express the RNP complex in yeast, aligning with Dr. Saito's recommendations.",
- months: "august",
+ months: "aug",
interview:<>
<QaBox q="Are you familiar with iGEM, by the way?" a="Of course, I know it."/>
<QaBox q="Did you participate yourself at some point?" a="Unfortunately, I didn't. I belong to an earlier generation. iGEM actually started relatively recently."/>
@@ -2017,7 +2017,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
These insights clarified the immediate and future steps required to move Precyse forward, particularly in terms of regulatory submissions, quality management, and production scale-up. </p>],
implementation: [<p>We used the insights from the expert to outline the possible next steps for Precyse. This included planning the collection of necessary preclinical data, setting up a GxP-compliant QMS, and preparing for regulatory submission. We also began drafting a strategy for process validation and scaling up production, ensuring that we are aligned with both regulatory and operational requirements. This expert feedback helped us establish a clearer path for the continued development of Precyse. </p>],
summary: "In our consultation with GxP expert Dr. Marcus Berger, we gained key insights to advance the Precyse project, focusing on regulatory strategy, quality management, and clinical development. He emphasized obtaining Scientific Advice from the Paul-Ehrlich-Institut (PEI) and collecting essential preclinical data, including toxicity and biodistribution studies. We also learned how to theoretically set up a GxP-compliant quality management system (QMS) following ICH Q10 guidelines and the importance of critical quality attributes (CQAs) in process validation. Dr. Berger provided guidance on scaling production and following ICH-GCP guidelines for clinical trials, especially for managing risks in gene therapies. This expert advice helped us plan the next steps for Precyse, including preclinical data collection, QMS setup, and production scale-up.",
- months: "September",
+ months: "sep",
interview:<>
<QaBox q="How do we define the regulatory strategy (e.g. IND/IMPD applications)?" a="The regulatory strategy includes the planning of clinical and preclinical development in accordance with applicable regulations, such as CTR 536/2014 in Europe. Planning, conduct, documentation, and reporting applies to clinical trials."/>
<QaBox q="What initial steps are necessary to prepare the submission to the competent authorities?" a="Firstly, a Scientific Advice should be requested from the competent authority. This enables early feedback on the planned development of the substance, which helps to optimise the submission strategy. Scientific advice from authorities such as the Paul Ehrlich Institute ensures that the requirements are correctly understood and implemented. It is also necessary to think about how you want to develop the substance."/>
@@ -2053,7 +2053,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>We employed several analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. TEM and SEM allowed us to visualize the structural morphology of the LNPs, providing detailed images to understand their size and shape on the nanometer scale. DLS was used to measure the size distribution of the particles in solution, while the zeta potential analysis gave us insight into the surface charge, which is crucial for understanding stability in suspension. </p>],
implementation: [<p>Thanks to the guidance and hands-on support of the Physical Chemistry team, we successfully completed these tests, gaining detailed insights into our LNPs that will be crucial for our project's further development. Their expertise not only streamlined the process but also ensured the reliability and accuracy of our results. Here a sneak peak of the results – take a look at the image of our SORT LNP taken via TEM. </p>],
summary: "We collaborated with the Physical Chemistry workgroup to accurately characterize our lipid nanoparticles (LNPs). Their expertise, particularly from Marco, Uwe, and Yvonne, was invaluable in selecting and applying various analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. This collaboration not only enhanced our understanding of the LNPs' size, shape, and stability but also ensured the reliability of our results. With their guidance, we successfully completed our tests, providing crucial insights for the project's advancement.",
- months: "September",
+ months: "sep",
pictureurl_interview: "https://static.igem.wiki/teams/5247/delivery/cryo-em.webp",
pictureurl_implementation: " https://static.igem.wiki/teams/5247/delivery/tem-sort-lnp1.webp",
},
@@ -2075,7 +2075,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Hakan generously agreed to carry out the transformation and prepare potential positive transformants for cultivation for us, leaving only the purification of the proteins from the supernatant for us to do. </p>],
implementation: [<p>Hakan performed the transformation of a pPIC9K-n3SpuFz1 construct we created into Yeast. Unfortunately, the first attempt of transformation did not yield any positive clones. However, we value his spontaneous and extensive support as a great contribution to our project. </p>],
summary: "We collaborated with the Physical Chemistry workgroup to accurately characterize our lipid nanoparticles (LNPs). Their expertise, particularly from Marco, Uwe, and Yvonne, was invaluable in selecting and applying various analytical techniques, including Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Dynamic Light Scattering (DLS), and zeta potential analysis. This collaboration not only enhanced our understanding of the LNPs' size, shape, and stability but also ensured the reliability of our results. With their guidance, we successfully completed our tests, providing crucial insights for the project's advancement.",
- months: "September",
+ months: "sep",
},
{
title: "M.Sc.",
@@ -2100,7 +2100,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Additionally, Benjamin recommended starting with small-scale tests (about 100 µL) before moving to larger formulations. The ratio of RNA to Chitosan is key to creating negatively charged particles, and a 2:1 ratio should be maintained. We will verify successful encapsulation using microscopic analysis and gel electrophoresis.
This knowledge has directly shaped our approach to using Chitosan. Our focus is now on forming stable RNA-Chitosan complexes, which can be encapsulated in LNPs. We’ve also learned the importance of optimizing concentrations to prevent aggregation or toxicity while ensuring the particles stay within the desired nanometer range. Microscopy and electrophoresis will now be key methods in our protocol to confirm complete RNA encapsulation within the LNPs. </p>],
summary: "In summary, the insights from Benjamin’s expertise were crucial in shaping our understanding of how to integrate Chitosan into our LNP formulations. Chitosan’s protective abilities for RNA, along with its heat stability, make it a valuable component in our project. However, its hydrophilic and cationic nature presents challenges for direct integration into LNP lipid shells, so we are focusing on its use as an encapsulation for the RNA. Benjamin’s advice on concentrations, molecular weight, and complex formation gave us a clear path forward, which will be validated through experimental testing. ",
- months: "september"
+ months: "sep"
},
{
title: "Priv. Doz. Dr. med.",
@@ -2119,7 +2119,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: [<p>Through this collaboration with the pathology department, we gained valuable insight into the structural integrity and differentiation of our ALI cultures. HE staining provided detailed information on the overall morphology of the cells, allowing us to assess cellular architecture, tissue organisation and any potential abnormalities. PAS staining provided additional insight by highlighting the presence of polysaccharides and mucosal substances, which are important indicators of tissue differentiation and barrier function in epithelial cultures. This histological analysis confirmed that the cultures had developed the expected cell types and structures, confirming the success of our experimental conditions.</p>],
implementation: [<p>The histological data obtained through the collaboration was instrumental in assessing the quality of our ALI cultures. By confirming that the cultures had developed properly, we were able to refine and optimise our experimental protocol. In particular, the information helped us to validate epithelial differentiation and assess the effectiveness of our culture techniques, and the ability to routinely use FFPE embedding, sectioning and special staining provided us with a robust set of tools for ongoing culture assessment and optimization in future experiments.</p>],
summary: "Collaboration with pathology was key to evaluating and validating ALI cultures, providing essential histological insights that refined protocols and established a reliable method for ongoing culture optimization.",
- months: "october"
+ months: "oct"
},
{
vorname: "Grand Jambooree in Paris",
@@ -2136,7 +2136,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
quoteVorname: "Isabell",
type: "meta",
summary: "As the team gears up for the Grand Jambooree in Paris, our focus has been on finalizing our presentation materials, including a dynamic presentation video that showcases our project and research findings. We are preparing for various formats of engagement, such as presentations and talks, where we’ll share our insights with fellow participants. Additionally, our poster session will provide an opportunity for interactive discussions, and we are bracing for the judging sessions that will critically evaluate our work.",
- months: "october"
+ months: "oct"
},
{
vorname: "Carry It Forward",
@@ -2155,7 +2155,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
{
vorname: "Homecoming",
@@ -2174,7 +2174,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
{
vorname: "Carry It Forward",
@@ -2193,7 +2193,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: [<p>As we move forward with our project, our intention is to continue our research and development at our university.
We believe that by building on our current findings, we can make significant contributions to the field.
Additionally, we are considering reaching out to Mattjis Bulcaen at KU Leuven for potential collaboration in the future, as their expertise could further enhance our work.</p>],
- months: "october"
+ months: "oct"
},
]
--
GitLab